Drug Trial Radar · NCT05142553
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,164
Actual
Start
Nov 15, 2021
Primary completion
May 29, 2023
Study completion May 29, 2023
Sponsor
- Lead sponsor
- Hipra Scientific, S.L.UIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the Pfizer-BioNTech (Comirnaty) COVID-19 vaccine at least 182 days prior to the booster dose in this study) versus a homologous booster (subjects who received the second dose of the Comirnaty COVID-19 vaccine at least 182 days prior to the booster dose in this study) will receive a third dose of the Comirnaty vaccine). The extension part of the study aims to compare the immunogenicity and safety of a fourth dose of PHH-1V in subjects with a primovaccination with Pfizer-BioNTech (Comirnaty) COVID-19 vaccine plus either a booster dose of Comirnaty or PHH-1V versus those with three vaccinations of Comirnaty.
Conditions
- SARS-CoV 2 Infection
Interventions
COVID-19 Vaccine HIPRABiological
Subjects will receive one injection of COVID-19 Vaccine HIPRA
Cominarty (Pfizer-BioNtech)Biological
Subjects will receive one injection of Cominarty Vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Changes of the immunogenicity against WuhanTime frame: 14 days
- Safety and tolerability of PHH-1V as third or fourth doseTime frame: 7 days
- Safety and tolerability of PHH-1V as third or fourth doseTime frame: 28 days
- Safety and tolerability of PHH-1V as third or fourth doseTime frame: 364 days
- Safety and tolerability of PHH-1V as third or fourth doseTime frame: Days 14, 28, 182, and 364
- Part B: Changes of the immunogenicity against Omicron BA.1Time frame: Day 14
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Hospital Clinic de Barcelona
Barcelona, Barcelona, Spain
Hospital Germans Trias I Pujol
Badalona, BARCELONA, Spain
Hospital Vall Hebron
Barcelona, BARCELONA, Spain
Hospital Universitari Dr. Josep Trueta
Girona, Girona, Spain
Hospital Gregorio Marañón
Madrid, Madrid, Spain
Hospital Universitario La Paz
Madrid, Madrid, Spain
Hospital Principe de Asturias
Meco, Madrid, Spain
Hospital Regional Universitario de Málaga
Málaga, Málaga, Spain
Hospital Clínico de Valencia
Valencia, Valencia, Spain
Hospital de Cruces
Barakaldo, VIZCAYA, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.